Ratings NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
16.03 ^USD	+3.22%		+25.82%	+7.37%

May. 02	NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue	MT
May. 02	BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
With an enterprise value anticipated at 2.75 times the sales for the current fiscal year, the company turns out to be overvalued.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
NOVOCURE LIMITED	+7.37%	1.67B	C-
SHOCKWAVE MEDICAL, INC.	+73.50%	12.41B	B-
PENUMBRA, INC.	-19.26%	8.14B	C+
MASIMO CORPORATION	+2.40%	7.2B	C-
GETINGE AB	+3.66%	5.93B	B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+11.89%	5.43B	D+
APT MEDICAL INC.	+37.45%	4.89B	-
ASAHI INTECC CO., LTD.	-19.75%	4.09B	B-
INARI MEDICAL, INC.	-35.58%	2.49B	C
SKAN GROUP AG	+0.74%	2.04B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes